1.4—Platform for Targeted Protein Degradation and Drug Discovery

This technology enables the engineering of a programmable protease with highly specific peptide hydrolysis, opening a new frontier in targeted protein degradation, one of the hottest areas in drug discovery. By unlocking the ability to degrade previously undruggable targets, it offers powerful therapeutic potential across oncology, neurodegeneration and beyond. With clear relevance to proteomics-driven companies like Amgen, this platform is primed for commercial development.

Inventor: Aaron Whiteley (CU Boulder Biochemistry)

Potential Applications: Health and Wellness, Biotech, Therapeutics